NASDAQ:RXDX Prometheus Biosciences (RXDX) Stock Forecast, Price & News $198.60 0.00 (0.00%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$198.51▼$198.7950-Day Range$106.47▼$198.7052-Week Range$22.31▼$198.99Volume1.09 million shsAverage Volume898,639 shsMarket Capitalization$9.50 billionP/E RatioN/ADividend YieldN/APrice Target$153.36 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Prometheus Biosciences MarketRank™ ForecastAnalyst RatingHold2.36 Rating ScoreUpside/Downside22.8% Downside$153.36 Price TargetShort InterestBearish14.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 8 Articles This WeekInsider TradingSelling Shares$105.75 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.84) to ($4.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.44 out of 5 starsMedical Sector944th out of 1,010 stocksPharmaceutical Preparations Industry471st out of 494 stocks 2.2 Analyst's Opinion Consensus RatingPrometheus Biosciences has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 4 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $153.36, Prometheus Biosciences has a forecasted downside of 22.8% from its current price of $198.60.Amount of Analyst CoveragePrometheus Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.40% of the float of Prometheus Biosciences has been sold short.Short Interest Ratio / Days to CoverPrometheus Biosciences has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Prometheus Biosciences has recently increased by 11.02%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrometheus Biosciences does not currently pay a dividend.Dividend GrowthPrometheus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXDX. Previous Next 2.1 News and Social Media Coverage News SentimentPrometheus Biosciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Prometheus Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for RXDX on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Prometheus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prometheus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $105,745,913.00 in company stock.Percentage Held by Insiders13.08% of the stock of Prometheus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.31% of the stock of Prometheus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prometheus Biosciences are expected to decrease in the coming year, from ($3.84) to ($4.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prometheus Biosciences is -56.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prometheus Biosciences is -56.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrometheus Biosciences has a P/B Ratio of 12.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prometheus Biosciences (NASDAQ:RXDX) StockPrometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.Read More Receive RXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RXDX Stock News HeadlinesMay 28, 2023 | fool.comPrometheus Biosciences (NASDAQ: RXDX)May 26, 2023 | americanbankingnews.comPrometheus Biosciences (NASDAQ:RXDX) Sees Unusually-High Trading VolumeMay 29, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 25, 2023 | americanbankingnews.comBrokerages Set Prometheus Biosciences, Inc. (NASDAQ:RXDX) PT at $162.14May 23, 2023 | msn.comPrometheus Biosciences gains after HSR waiting for sale to Merck expiresMay 23, 2023 | barrons.comSHAREHOLDER ALERT: Weiss Law Investigates Prometheus Biosciences, Inc.May 18, 2023 | finance.yahoo.comWhat Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice?May 18, 2023 | americanbankingnews.comPrometheus Biosciences (NASDAQ:RXDX) Sees Strong Trading VolumeMay 29, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 12, 2023 | finance.yahoo.comPrometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?May 11, 2023 | msn.comJefferies Downgrades Prometheus Biosciences (RXDX)May 11, 2023 | msn.comRBC Capital Maintains Prometheus Biosciences (RXDX) Sector Perform RecommendationMay 11, 2023 | americanbankingnews.comJefferies Financial Group Lowers Prometheus Biosciences (NASDAQ:RXDX) to HoldMay 9, 2023 | yahoo.comPrometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressMay 2, 2023 | americanbankingnews.comPrometheus Biosciences, Inc. (NASDAQ:RXDX) Receives $155.83 Consensus Price Target from BrokeragesMay 2, 2023 | americanbankingnews.comPrometheus Biosciences, Inc. (NASDAQ:RXDX) Given Average Recommendation of "Hold" by BrokeragesMay 1, 2023 | msn.comAbbvie, Bristol Myers competed with Merck in sale of Prometheus - reportApril 29, 2023 | finance.yahoo.comWith 67% ownership, Prometheus Biosciences, Inc. (NASDAQ:RXDX) boasts of strong institutional backingApril 29, 2023 | americanbankingnews.comPrometheus Biosciences (NASDAQ:RXDX) Sets New 1-Year High at $195.00April 26, 2023 | americanbankingnews.comHead to Head Survey: Prometheus Biosciences (NASDAQ:RXDX) vs. 9 Meters Biopharma (NASDAQ:NMTR)April 21, 2023 | finance.yahoo.comPharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other UpdatesApril 20, 2023 | finance.yahoo.comWhy Prometheus Biosciences Stock Is Skyrocketing This WeekApril 20, 2023 | americanbankingnews.comPrometheus Biosciences (NASDAQ:RXDX) Downgraded by GuggenheimApril 20, 2023 | americanbankingnews.comPiper Sandler Lowers Prometheus Biosciences (NASDAQ:RXDX) to NeutralApril 20, 2023 | americanbankingnews.comPrometheus Biosciences (NASDAQ:RXDX) Cut to "Neutral" at Credit Suisse GroupApril 19, 2023 | americanbankingnews.comStifel Nicolaus Lowers Prometheus Biosciences (NASDAQ:RXDX) to HoldApril 19, 2023 | americanbankingnews.comPrometheus Biosciences (NASDAQ:RXDX) Stock Rating Lowered by GuggenheimSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RXDX Company Calendar Last Earnings5/09/2023Today5/29/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXDX CUSIPN/A CIK1557421 Webignyta.com Phone858-422-4300FaxN/AEmployees72Year Founded1995Price Target and Rating Average Stock Price Forecast$153.36 High Stock Price Forecast$200.00 Low Stock Price Forecast$60.00 Forecasted Upside/Downside-22.8%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,750,000.00 Net Margins-3,768.76% Pretax Margin-3,768.76% Return on Equity-33.50% Return on Assets-29.59% Debt Debt-to-Equity Ratio0.04 Current Ratio37.56 Quick Ratio37.56 Sales & Book Value Annual Sales$4.00 million Price / Sales2,376.89 Cash FlowN/A Price / Cash FlowN/A Book Value$16.12 per share Price / Book12.32Miscellaneous Outstanding Shares47,813,000Free Float46,187,000Market Cap$9.50 billion OptionableNot Optionable Beta-0.50 Social Links Key ExecutivesMr. Mark C. McKenna (Age 42)Pres, CEO & Chairman Comp: $2.22MDr. Keith W. Marshall M.B.A. (Age 54)MBA, Ph.D., Chief Financial Officer Comp: $971.67kMr. Mark Stenhouse (Age 55)Chief Operating Officer Comp: $679.71kDr. Allison Luo M.D. (Age 49)Chief Medical Officer Comp: $827.97kDr. Olivier Laurent Ph.D. (Age 50)Chief Scientific Officer & Head of R&D Ms. Noel KurdiVP of Investor Relations & CommunicationsMr. Timothy K. Andrews Esq. (Age 43)Gen. Counsel & Sec. Ms. Nori Ebersole (Age 57)Chief People Officer Dr. Thierry Dervieux DABCC (Age 54)Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director Mr. Chris DoughtyChief Bus. OfficerMore ExecutivesKey CompetitorsDr. Reddy's LaboratoriesNYSE:RDYApellis PharmaceuticalsNASDAQ:APLSUnited TherapeuticsNASDAQ:UTHRTeva Pharmaceutical IndustriesNYSE:TEVAJazz PharmaceuticalsNASDAQ:JAZZView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 555 shares on 5/26/2023Ownership: 0.015%Legato Capital Management LLCSold 1,557 shares on 5/25/2023Ownership: 0.017%New York State Common Retirement FundSold 8,762 shares on 5/18/2023Ownership: 0.059%AQR Capital Management LLCSold 1,800 shares on 5/16/2023Ownership: 0.017%Sea Otter Advisors LLCBought 3,000 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RXDX Stock - Frequently Asked Questions Should I buy or sell Prometheus Biosciences stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares. View RXDX analyst ratings or view top-rated stocks. What is Prometheus Biosciences' stock price forecast for 2023? 11 brokers have issued 12 month price targets for Prometheus Biosciences' stock. Their RXDX share price forecasts range from $60.00 to $200.00. On average, they predict the company's stock price to reach $153.36 in the next year. This suggests that the stock has a possible downside of 22.8%. View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts. How have RXDX shares performed in 2023? Prometheus Biosciences' stock was trading at $110.00 on January 1st, 2023. Since then, RXDX stock has increased by 80.5% and is now trading at $198.60. View the best growth stocks for 2023 here. When is Prometheus Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our RXDX earnings forecast. How were Prometheus Biosciences' earnings last quarter? Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.06. The biopharmaceutical company earned $1.11 million during the quarter, compared to analyst estimates of $0.46 million. Prometheus Biosciences had a negative trailing twelve-month return on equity of 33.50% and a negative net margin of 3,768.76%. The firm's revenue was down 71.8% on a year-over-year basis. What ETFs hold Prometheus Biosciences' stock? ETFs with the largest weight of Prometheus Biosciences (NASDAQ:RXDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Renaissance IPO ETF (IPO), Harbor Health Care ETF (MEDI), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Prometheus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD). When did Prometheus Biosciences IPO? (RXDX) raised $126 million in an IPO on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO. What is Prometheus Biosciences' stock symbol? Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX." Who are Prometheus Biosciences' major shareholders? Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RTW Investments LP (6.88%), BlackRock Inc. (5.89%), Fred Alger Management LLC (2.79%), Perceptive Advisors LLC (2.66%), State Street Corp (2.60%) and FMR LLC (2.41%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse, Perceptive Advisors Llc and Sinai Intellectual Prop Cedars. View institutional ownership trends. How do I buy shares of Prometheus Biosciences? Shares of RXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prometheus Biosciences' stock price today? One share of RXDX stock can currently be purchased for approximately $198.60. How much money does Prometheus Biosciences make? Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $9.50 billion and generates $4.00 million in revenue each year. The biopharmaceutical company earns $-141,750,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis. Does Prometheus Biosciences have any subsidiaries? The following companies are subsidiares of Prometheus Biosciences: Prometheus Laboratories Inc..Read More How can I contact Prometheus Biosciences? Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com. This page (NASDAQ:RXDX) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prometheus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.